Shots:
- OSE Immunotherapeutics has reported the topline P-II (TEDOVA/GINECO-OV244b/ENGOT-ov58) trial results evaluating Tedopi (OSE2101) ± Keytruda as a maintenance treatment in pts with Pt-sensitive recurrent ovarian cancer (PSOC)
- Trial enrolled 185 pts with PSOC who progressed after or were ineligible for PARP inhibitors & Avastin. Pts achieving CR, PR, or stable disease after Pt-based therapy were randomized to either best supportive care (Arm A), Tedopi monotx. (Arm B), or Tedopi + Keytruda (Arm C)
- Trial met its 1EP, showing improved PFS for Arm C vs Arm A, with a 28% reduction in the risk of progression or death (mPFS: 4.1 vs 2.8mos.); data to be presented at ASCO’26
Ref: Globenewswire | Image: OSE | Press Release
Related News: Merck Reports the P-III (TroFuse-005) Trial Data on Sacituzumab Tirumotecan for Advanced or Recurrent Endometrial Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
